When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GNMSF - Genmab: Monoclonal Antibody Experts Low Risk Business Model
Genmab A/S Dkk
Genmab currently has aided and/or partnered in the development of four FDA approved monoclonal antibody therapies.
While not the owners, developers, or manufacturers of most of these therapies, the company earns money via licensing of their novel and innovative technology.
This will allow for steady revenue and earnings growth well into the future, giving investors a safe bet for steady accumulation of a stock in the biotech industry.